CTLA4 and nonpapillary renal cell carcinoma: Considering the upregulation of multiple different immune checkpoints, including CD274, CTLA4, HAVCR2, LAG3, PDCD1, PDCD1LG2 and TIGIT, double or triple ICIs combination therapy might be promising among ccRCC with BCAM-low expression.